Progression of adenomyosis magnetic resonance imaging features under ulipristal acetate for symptomatic fibroids
Authors:
- 1 March 2021
- journal article
- research article
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 42 (3) , 661-668
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Long-term treatment of uterine fibroids with ulipristal acetate☆Fertility and Sterility, 2014
- Clinical characteristics indicating adenomyosis coexisting with leiomyomas: a retrospective, questionnaire-based studyFertility and Sterility, 2014
- Endometrial Morphology After Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator, Ulipristal AcetateInternational Journal of Gynecological Pathology, 2012
- Four subtypes of adenomyosis assessed by magnetic resonance imaging and their specificationAmerican Journal of Obstetrics and Gynecology, 2012
- Ulipristal Acetate versus Placebo for Fibroid Treatment before SurgeryNew England Journal of Medicine, 2012
- Ulipristal Acetate versus Leuprolide Acetate for Uterine FibroidsNew England Journal of Medicine, 2012
- Promoter Hypermethylation of Progesterone Receptor Isoform B (PR-B) in Adenomyosis and Its Rectification by a Histone Deacetylase Inhibitor and a Demethylation AgentReproductive Sciences, 2010
- Ultrasound scan and magnetic resonance imaging for the diagnosis of adenomyosis: systematic review comparing test accuracyActa Obstetricia et Gynecologica Scandinavica, 2010
- Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applicationsHuman Reproduction Update, 2005
- Functional characterization of somatic point mutations of the human estrogen receptor α (hERα) in adenomyosis uteriMolecular Human Reproduction, 2004